Find product information about medicines

AI Summary

This MHRA guidance outlines the UK’s regulatory framework for accessing medicinal information, including Summaries of Product Characteristics (SPC), Patient Information Leaflets (PIL), and Public Assessment Reports (PAR). While the document does not name a specific company or list inspection dates and violations—as it is a general regulatory notice rather than an enforcement report—it establishes critical safety protocols. The guidance details the 'Additional Monitoring' process, identified by a black inverted triangle symbol, which signals that a medicine (often containing a new active substance) is under intense scrutiny for a minimum of five years. Under the Windsor Framework implementation on January 1, 2025, the MHRA converted Great Britain-specific marketing authorizations into UK-wide licenses. The required actions for healthcare professionals and the public involve using the MHRA’s search services to stay informed and reporting all suspected adverse reactions for monitored products via the Yellow Card scheme. This oversight ensures that the Commission on Human Medicines (CHM) can evaluate safety data throughout a product’s lifecycle, particularly during its initial years on the market or following major safety reviews.